Resources
Summary of the main discussions and way forward
Beta-variant recombinant booster vaccine elicits broad cross-reactive neutralization of SARS-CoV-2 including Omicron variants. Heliyon. 2024 Mar 15;10(5):e27033. doi: 10.1016/ j.heliyon.2024.e27033
Planas D, Peng L, Zheng L, Guivel-Benhassine F, Staropoli I, Porrot F, Bruel T, Bhiman JN, Bonaparte M, Savarino S, de Bruyn G, Chicz RM, Moore PL, Schwartz O, Sridhar S.
Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2. iScience . 2024 Jul 19;27(7):110354. doi: 10.1016/j.isci.2024.110354.
Planchais C, Fernández I, Chalopin B, Bruel T, Rosenbaum P, Beretta M, Dimitrov JD, Conquet L, Donati F, Prot M, Porrot F, Planas D, Staropoli I, Guivel-Benhassine F, Baquero E, van der Werf S, Haouz A, Simon-Lorière E, Montagutelli X, Maillère B, Rey FA, Guardado-Calvo P, Nozach H, Schwartz O, Mouquet H..
Structural basis of TMPRSS2 zymogen activation and recognition by the HKU1 seasonal coronavirus. Cell. 2024 Aug 8;187(16):4246-4260.e16. doi: 10.1016/j.cell.2024.06.007.
Fernández I, Saunders N, Duquerroy S, Bolland WH, Arbabian A, Baquero E, Blanc C, Lafaye P, Haouz A, Buchrieser J, Schwartz O, Rey FA.
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun. 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S, Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O.
Modeling memory B cell responses in a lymphoid organ-chip to evaluate mRNA vaccine boosting. J Exp Med. 2024 Oct 7;221(10). doi: 10.1084/jem.20240289.
Jeger-Madiot R, Planas D, Staropoli I, Debarnot H, Kervevan J, Mary H, Collina C, Fonseca BF, Robinot R, Gellenoncourt S, Schwartz O, Ewart L, Bscheider M, Gobaa S, Chakrabarti LA.
Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodies. Pathogens and Immunity. 2024;10(1):1–11. doi: 10.20411/pai.v10i1.752
Planas D, Staropoli I, Planchais C, Yab E, Jeyarajah B, Rahou Y, Prot M, Guivel-Benhassine F, Lemoine F, Enouf V, Simon-Loriere E, Mouquet H, Rameix-Welti M-A, Schwartz O.